Christoph Licht

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus et al. · New England Journal of Medicine · 2013 · 1.5K citations · Full text

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Timothy H.J. Goodship, H. Terence Cook, Fádi Fakhouri et al. · Kidney International · 2016 · 674 citations · Full text

Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test

Anath C. Lionel, Gregory Costain, Nasim Monfared et al. · Genetics in Medicine · 2017 · 551 citations · Full text

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

Christoph Licht, Larry A. Greenbaum, Petra Muus et al. · Kidney International · 2015 · 406 citations · Full text

Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency

Mihály Józsi, Christoph Licht, Svante Zipfel et al. · Blood · 2007 · 352 citations